Table 3.
Distribution of CYP2C19 genotypes, CYP2C19*2 and CYP2C19*3 loss-of-function alleles in the study population
| Genotype/allele | Phenotype | Total (n = 2,982) | Controls (n = 1,110) | Hypertensive patients (n = 1,872) | P value |
|---|---|---|---|---|---|
| Genotypes | |||||
| *1/*1 | Extensive metabolizer | 1216(40.8%) | 535(48.2%) | 681(36.4%) | < 0.001# |
| *1/*2 | Intermediate metabolizer | 1209(40.5%) | 409(36.8%) | 800(42.7%) | |
| *1/*3 | 190(6.4%) | 67(6.0%) | 123(6.6%) | ||
| *2/*2 | Poor metabolizer | 267(9.0%) | 65(5.9%) | 202(10.8%) | |
| *2/*3 | 92(3.1%) | 31(2.8%) | 61(3.3%) | ||
| *3/*3 | 8(0.3%) | 3(0.3%) | 5(0.3%) | ||
| Alleles | |||||
| *1 | 3831(64.2%) | 1546(69.6%) | 2285(61.0%) | < 0.001 | |
| *2 | 1835(30.8%) | 570(25.7%) | 1265(33.8%) | ||
| *3 | 298(5.0%) | 104(4.7%) | 194(5.2%) |
#, Comparison of the proportion of extensive metabolizer, intermediate metabolizer, and poor metabolizer between hypertensive patients and control group